Vensica Medical Ltd.

Vensica Medical Ltd. specializes in innovative urology therapeutics, notably through its flagship product, Vibe®, which delivers targeted ultrasound drug therapy for bladder conditions. Founded in 2014 and headquartered in Netanya, Israel, Vensica Medical Ltd. is focused on developing advanced treatment options in urology.

The company has engaged in six investment deals, with its most recent funding round occurring on October 28, 2024, which raised USD 11. 00 mn led by Israel Biotech Fund and included contributions from Laborie Medical Technologies Corp. and Merz Therapeutics. Avner Geva, the CEO and founder, has guided the company through its strategic initiatives since inception.

Vensica is dedicated to pioneering advanced urology therapeutics, primarily through its flagship product, Vibe®, a needle-free ultrasound drug delivery device for localized treatment of bladder conditions. Vibe® uses innovative ultrasound technology to microinject precise doses of medications, like Xeomin®, directly into the bladder wall, aimed at providing controlled therapies for overactive bladder. The company's pipeline also includes ViXe, which combines Xeomin® with the Vibe® system for improved therapeutic outcomes, targeting urologists and specialty healthcare providers across North America and Europe. Vensica's revenue model relies on partnerships and agreements within the healthcare sector, specifically targeting urology specialists and clinical institutions.

The company has recently closed a USD 11. 00 mn investment aimed at advancing its development, indicating robust investor confidence in its revenue potential. Revenue generation is expected through procurement agreements with healthcare facilities for the purchase of Vibe® and ViXe, which are positioned as advanced therapeutic options in urology. In October 2024, Vensica Medical Ltd.

secured USD 11. 00 mn in venture funding to expedite its Phase 2 clinical trials for overactive bladder treatment using botulinum toxin, specifically across the US and Europe. The company plans to enhance its product offerings with new developments and expand its presence in significant healthcare markets, utilizing recent funding to support these initiatives.